汉商集团股份有限公司2025 年半年度报告 公司代码：600774 公司简称：汉商集团 汉商集团股份有限公司 汉商集团股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人阎志、主管会计工作负责人张镇涛及会计机构负责人（会计主管人员）张琳声 明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 不分配，不转增。 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性陈述因存在不确定性，不构成本公司对投资 者的实质性承诺，敬请投资者注意投资风险。 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风险提示 报告期内，不存在对公 ...

Market Overview - A total of 58 stocks in the A-share market hit the daily limit, with 51 stocks after excluding 7 ST stocks, and an overall limit rate of 50.88% [1] Top Performers - China Electric Power Construction Company (中国电建) had the highest limit order volume with 7.5033 million hands, followed by Tibet Tianlu (西藏天路) with 2.0645 million hands, and China Railway Construction Heavy Industry (铁建重工) with 1.8256 million hands [2] - In terms of limit order funds, 20 stocks had over 100 million yuan in limit orders, with China Electric Power Construction leading at 5.08 billion yuan, followed by Tibet Tianlu at 2.632 billion yuan, and China Railway Construction Heavy Industry at 1.3 billion yuan [4] Industry Highlights Hydropower Sector - China Electric Power Construction is a leading player in hydropower and pumped storage construction, with new hydropower contracts signed in 2024 amounting to 142.896 billion yuan, representing 18.73% of its energy business, a year-on-year increase of 26.35% [4] - Other stocks in the hydropower sector that hit the limit include Tibet Tianlu, Poly United (保利联合), and Shanhe Intelligent (山河智能) [5] Nuclear Fusion Sector - The establishment of China Fusion Energy Co., in which China Nuclear Power (中国核电) has a stake, was announced, indicating a focus on controlled nuclear fusion technology [8] - Key players like GuoJi Heavy Equipment (国机重装) are actively developing critical components for fusion devices [8] Pharmaceutical Sector - Zhendong Pharmaceutical (振东制药) is focusing on innovative drugs, particularly in oncology and dermatology [9] - Seer Medical (塞力医疗) has developed a therapeutic vaccine for hypertension, which is recognized as a national Class I innovative drug [9] - HanShang Group (汉商集团) has a diverse portfolio of 92 pharmaceutical products across various therapeutic areas [9] Related ETFs - The Green Power ETF (绿电ETF) tracks the China Securities Green Power Index, with a recent five-day change of 1.56% and a price-to-earnings ratio of 17.54 times [11]

Market Overview - On July 18, the A-share market saw a total of 52 stocks hit the daily limit, with 46 stocks remaining after excluding 6 ST stocks, resulting in an overall limit-up rate of 71.23% [1] Top Performers - The highest limit-up order volume was recorded by Renmin Tongtai with 393,600 hands, followed by Shangwei New Materials, Meibang Shares, Zhongse Shares, and Yanhua Intelligent with limit-up orders of 280,700 hands, 222,400 hands, 220,900 hands, and 181,100 hands respectively [2] - Shangwei New Materials achieved an 8-day consecutive limit-up, while Lansheng Shares had 6 consecutive limit-ups, and several other stocks also recorded multiple consecutive limit-ups [2] Significant Transactions - In terms of order amount, 13 stocks had limit-up funds exceeding 100 million yuan, with Shangwei New Materials, Meibang Shares, and Renmin Tongtai leading at 939 million yuan, 519 million yuan, and 364 million yuan respectively [3] - Shangwei New Materials reached a "20cm" limit-up again, becoming the second stock in A-share history to achieve eight consecutive "20cm" limit-ups, following an announcement of a potential acquisition of controlling rights by Zhiyuan Robotics [3] Industry Highlights Lithium Battery Sector - Stocks in the lithium battery sector that hit the limit-up include Jinyuan Shares, Guoji General, Jiuwu High-Tech, and Shengxin Lithium Energy [4] - The futures price of lithium carbonate increased by 2.82% on July 18, with a 17.42% rise over the past 20 trading days [4] Performance Growth - Hai Li Shares is expected to achieve a net profit attributable to shareholders of 30.5 million to 36 million yuan in the first half of the year, representing a year-on-year growth of 625.83% to 756.71% [8] - Yanhua Intelligent anticipates a net profit of 3.5 million to 5.25 million yuan, marking a turnaround from losses [9] - Dongfang Zircon is projected to report a net profit of 25 million to 34 million yuan, also indicating a return to profitability [10] Pharmaceutical Sector - Hancheng Group has 92 types of pharmaceutical products on sale, covering various fields including digestive and respiratory systems [11] - Renmin Tongtai aims to establish a professional health service platform in Heilongjiang Province, focusing on four main business areas [12] - Anglikang's ALK-N001 project is currently in Phase I clinical trials, with approval expected by April 2025 [13] ETF Insights - The Food and Beverage ETF (product code: 515170) has seen a recent decline of 1.40% over the past five days, with a current PE ratio of 20.20 times [15] - The Gaming ETF (product code: 159869) has decreased by 2.12% in the last five days, with a PE ratio of 43.40 times [15] - The Cloud Computing 50 ETF (product code: 516630) has increased by 7.95% over the past five days, with a PE ratio of 110.72 times [16]

Meeting Overview - The company held a performance briefing for the fiscal year 2024 and the first quarter of 2025 on May 12, 2025, from 15:00 to 16:00 [1][2] - The meeting was attended by key executives including the vice chairman and independent directors, facilitating interaction with investors [2] Differentiation Strategy - The company aims to maintain its competitive edge through a diversified product portfolio, including 92 pharmaceutical products across various therapeutic areas [3] - A comprehensive sales system has been established with over 400 sales personnel covering 31 provinces, reaching more than 10,000 hospitals and nearly 300,000 retail pharmacy stores [4] - The company emphasizes a specialized R&D platform to drive innovation, with ongoing clinical studies for its global Class I innovative drug projects [5][10] Medical Device Business - In 2024, the medical device segment generated revenue of approximately 82.57 million yuan, reflecting a year-on-year growth of 14.57% [7] - The product line includes absorbable medical devices, which are gaining traction in various surgical fields, contributing to sustained growth [8] R&D Investment - The total R&D expenditure for 2024 was approximately 4.51 million yuan, focusing on enhancing product lines and ensuring sustainable development [9] Financial Performance - For the first quarter of 2025, the company reported total revenue of approximately 257.42 million yuan, with net profit attributable to shareholders at approximately 2.76 million yuan [11] - The company’s exhibition business generated revenue of approximately 70.25 million yuan in 2024, showing a growth of 3.81% [12] Industry Outlook - The pharmaceutical industry is experiencing diversification and structural changes, presenting both opportunities and challenges for companies [18] - The medical device sector is witnessing accelerated domestic substitution and technological innovation, supported by favorable government policies [18] - The commercial retail sector is becoming increasingly competitive, with brands focusing on professional and differentiated strategies to meet consumer demands [19] - The exhibition industry is expected to continue its rapid growth, leveraging digital platforms and innovative approaches to enhance user experience [19]

Core Viewpoint - Han Commercial Group (600774.SH) reported a revenue of 1.175 billion yuan for 2024, a decrease of 15.41% year-on-year, primarily due to market fluctuations and policy adjustments in the medical sector [1] Group 1: Financial Performance - The company experienced a revenue decline attributed to the medical sector's income reduction caused by market environment changes and policy adjustments [1] - The company anticipates a recovery in performance by 2025 as it deepens its "Big Health + Big Business" dual main business strategy [1] Group 2: Pharmaceutical Sector - Han Commercial Group has expanded its presence in the big health sector, focusing on chemical drugs, traditional Chinese medicine, and medical devices through its subsidiary, Dikon Pharmaceutical [2] - The company invested over 50 million yuan in R&D for 2024, emphasizing innovation and product development [1] - The company holds complete intellectual property rights for its global Class I innovative drug DDCI-01, which has completed Phase II clinical trials and is entering Phase III for indications related to pulmonary arterial hypertension and benign prostatic hyperplasia [1] Group 3: Traditional Chinese Medicine - The company is progressing with the resumption of production for Dikon Traditional Chinese Medicine following the bankruptcy restructuring of Dongfang Pharmaceutical, achieving the market launch of 13 products [2] - The star product, Tongqiao Bi Yan Granules, sold over 13 million boxes in 2024, marking a 20% increase year-on-year [2] Group 4: Medical Devices - Dikon Zhongke, a subsidiary, has seen growth in its absorbable medical devices, including absorbable bone fixation screws and membranes, with successful bids in various provinces [2] - The company is advancing the development of new medical devices, obtaining multiple registration certificates and inspection approvals [2] Group 5: Assisted Reproductive Technology - The company plans to enhance support for key disciplines in assisted reproduction, aiming to establish a well-known specialty hospital in the field [2] Group 6: Commercial Exhibition Sector - The company is adapting its shopping centers and business operations to market changes, exploring new business models such as low-altitude logistics [3] - The transformation of the former Wuhan wedding photo material city into the Han Chao Z6 project aims to attract a younger demographic [3] - The Wuhan International Exhibition Center is undergoing operational upgrades to create a new service model for the exhibition industry [3] Group 7: Future Strategy - The company aims to strengthen its pharmaceutical sector by focusing on traditional Chinese medicine, enhancing sales, and driving R&D [3] - The commercial sector will focus on precise positioning and upgrading to enhance profitability and invigorate traditional brands [3]